Single-Cell Multiomics Market to Surge from $2.99 Billion to $18.20 Billion by 2035, Driven by Precision Medicine and AI
核心洞察
The global single-cell multiomics (搜索) market, valued at USD 2.99 billion in 2025, is projected to reach USD 18.20 billion by 2035 at a CAGR of 19.81%, according to SNS Insider.
Oncology dominated the application segment with a 38.90% revenue share in 2025, while single-cell proteomics is expected to grow at the fastest CAGR of 23.16% through 2035.
Droplet-based microfluidics accounted for 56.30% of market revenue in 2025, though spatial-omics platforms are forecast to achieve the highest CAGR of 24.50%.
The global single-cell multiomics (搜索) market is poised for extraordinary expansion over the next decade, with a new analysis from SNS Insider projecting growth from USD 2.99 billion in 2025 to USD 18.20 billion by 2035, reflecting a compound annual growth rate (CAGR) of 19.81%. This surge is being propelled by accelerating demand for sophisticated cellular analysis platforms across oncology, immunology, neurology, and rare disease research, as pharmaceutical companies and academic institutions alike seek deeper insights into complex biological processes.
"Single-cell multiomics (搜索) is transforming biomedical research by enabling scientists to examine cellular complexity with unprecedented precision," said SNS Insider analyst Parry Kardani. "Continued advances in sequencing technologies, spatial biology, and AI-enabled analytics are expected to unlock significant opportunities for precision medicine and next-generation therapeutic development over the coming decade."
Oncology Leads Applications as Proteomics Gains Momentum
Oncology research accounted for 38.90% of total market revenue in 2025, underscoring the central role of single-cell multiomics (搜索) in cancer (搜索) research and the growing emphasis on precision oncology. The immunology segment is forecast to grow at the fastest CAGR among applications, reaching 22.16% over the forecast period.
In terms of product categories, single-cell genomics captured 34.20% of global revenue in 2025, reflecting widespread adoption across genomic research, disease profiling, and precision medicine initiatives. However, single-cell proteomics is expected to register the most rapid expansion, with a projected CAGR of 23.16% through 2035, fueled by increasing demand for protein-level analysis and biomarker discovery in research settings.
Droplet-Based Microfluidics Dominates, Spatial-Omics Accelerates
Droplet-based microfluidics represented 56.30% of market revenue in 2025, a position attributed to its scalability and capacity for high-throughput single-cell analysis. Yet spatial-omics platforms are anticipated to achieve the highest growth rate, with a CAGR of 24.50%, driven by rising adoption of tissue-level analysis and spatial biology approaches that provide critical contextual information about cellular organization.
Pharma and Biotech Drive Commercial Adoption
Pharmaceutical and biotechnology companies constituted the largest end-user segment, generating 39.10% of global revenue in 2025. Academic and research institutions are projected to grow at the highest CAGR of 21.29%, reflecting increasing investment in foundational research infrastructure and multiomics capabilities.
The integration of artificial intelligence, cloud computing, and next-generation sequencing is accelerating the analysis of complex biological datasets, enabling research organizations to shorten discovery timelines and identify biomarkers for precision medicine applications across diverse therapeutic areas.
Regional Dynamics: North America Leads, Asia Pacific Surges
North America held a dominant 41.85% share of global market revenue in 2025, supported by robust research infrastructure, widespread availability of advanced sequencing technologies, and sustained investment in precision medicine. The Asia Pacific region is projected to experience the strongest growth through 2035, driven by expanding biotechnology sectors, increased research funding, genomics initiatives, and advancements in life sciences technologies across China, Japan, South Korea, and India.
Key companies shaping the competitive landscape include Illumina, 10x Genomics (搜索), Thermo Fisher Scientific (搜索), Danaher Corporation (搜索), Bio-Rad Laboratories (搜索), Agilent Technologies (搜索), Roche, QIAGEN, Oxford Nanopore Technologies (搜索), and Bruker Corporation (搜索). Growing demand for next-generation sequencing, spatial biology platforms, and integrated software and analysis solutions is intensifying competition as major life sciences players commit substantial resources to innovation in this space.